Profile
Astrid Borkowski currently works at HilleVax, Inc., as Chief Medical Officer from 2021.
Dr. Borkowski also formerly worked at Novartis Vaccines & Diagnostics, Inc., as Chief Medical Officer-European Region and Takeda Pharmaceuticals International, Inc., as Vice President & Head-Clinical Development.
Dr. Borkowski received her doctorate degree from Humboldt-Universität zu Berlin.
Astrid Borkowski active positions
| Companies | Position | Start |
|---|---|---|
| HILLEVAX, INC. | Chief Tech/Sci/R&D Officer | 2021-02-28 |
Former positions of Astrid Borkowski
| Companies | Position | End |
|---|---|---|
Novartis Vaccines & Diagnostics, Inc.
Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Corporate Officer/Principal | - |
Takeda Pharmaceuticals International, Inc.
Takeda Pharmaceuticals International, Inc. Miscellaneous Commercial ServicesCommercial Services Provides management consulting for pharmaceutical businesses | Corporate Officer/Principal | - |
Training of Astrid Borkowski
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Novartis Vaccines & Diagnostics, Inc.
Novartis Vaccines & Diagnostics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Humboldt-Universität zu Berlin
Humboldt-Universität zu Berlin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Takeda Pharmaceuticals International, Inc.
Takeda Pharmaceuticals International, Inc. Miscellaneous Commercial ServicesCommercial Services Provides management consulting for pharmaceutical businesses | Commercial Services |
HilleVax, Inc.
HilleVax, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in the development and commercialization of novel vaccine candidates | Health Technology |
- Stock Market
- Insiders
- Astrid Borkowski
















